Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee.

Grupp SA, Frangoul H, Wall D, Pulsipher MA, Levine JE, Schultz KR
Pediatr Blood Cancer. 2006 46 (4): 414-21

PMID: 16463346 · DOI:10.1002/pbc.20800

Preliminary studies indicate that G-CSF-primed marrow harvesting may result in a graft with increased mononuclear cells collected, increased CD34(+) stem and progenitor cell dose and a potential for more rapid engraftment. Increased cell dose plus other potential positive effects of G-CSF priming have resulted in improved survival in non-randomized preliminary studies. These benefits may be available without the increased risk of chronic graft versus host disease (GVHD) that is experienced with allogeneic peripheral blood stem cell (PBSC) transplant. A phase III Children's Oncology Group (COG)/Pediatric Blood and Marrow Transplant Consortium (PBMTC) trial comparing G-CSF-primed marrow to standard marrow has been proposed. This document reviews background studies of G-CSF-primed marrow and addresses benefits and risks of G-CSF administration to normal pediatric donors. We conclude that the approach is promising and warrants further study. Risks of G-CSF to the donor are minimal and benefits to both donor and recipient may occur.

MeSH Terms (11)

Child Consensus Graft vs Host Disease Granulocyte Colony-Stimulating Factor Hematologic Neoplasms Humans Peripheral Blood Stem Cell Transplantation Risk Assessment Siblings Tissue Donors Transplantation, Homologous

Connections (1)

This publication is referenced by other Labnodes entities: